Deltagen BioServices deltagen.com


Public lists: Pharma Startups (4733)

Deltagen BioServices provides high quality, regulatory-compliant services supporting the development and commercialization of biopharmaceutical products. Services include adventitious agent detection for virus, bacteria, mycoplasma, fungi, etc.; vaccine and cellular therapy Phase I & II clinical lot manufacturing; and cell banking and characterization.

Deltagen BioServices provides high quality, regulatory-compliant services supporting the development and commercialization of biopharmaceutical products. Services include adventitious agent detection for virus, bacteria, mycoplasma, fungi, etc.; vacc...Show all

Company (Alive / Active)

Phone: 650-569-5100

Fax:

347 Phoenixville Pike
Malvern, 19355
Pennsylvania, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Deltagen BioServices $60.6M Jul 18, 2012
See all 15 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Deltagen BioServices Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 15 investors

Competitors

Company Status Description Investors

NeuroGenomeX

Madison, Wisconsin, United States
Alive / ActiveNeuroGenomeX is a drug discovery company developing novel treatments for diseases of the brain and nervous system. The current NeuroGenomeX discovery program is focused on therapeutic target areas of epilepsy and traumatic brain injury. NeuroGenomeX is advancing its lead drug candidate, 2-deoxy-D-glucose (2DG), as an anticonvulsant that stops seizures and has beneficial effects against adverse long-term consequences of epilepsy. 2DG also has shown favorable therapeutic neuroprotective effects in...Show allLogin to see details

Velocity11

Menlo Park, California, United States
AcquiredVelocity11 broadly covers the life science automation market, with a concentration in drug discovery, genomics, and proteomics applications. Through direct distribution, value added reseller channels, and a multi-continent customer service, applications, and support organization, Velocity11 strives to deliver an outstanding user experience to our customers globally. Velocity11 works to maintain an intimate relationship with each of our customers across over 3,500 installations, including all ...Show allLogin to see details
See all 15 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)